Gradient Bioconvergence Participates in 'BIO USA' for 3rd Consecutive Year

– Introducing PDO banking, iPSC-derived brain organoids, AI target discovery platform, etc. through a standalone booth

– “We will expand global partnerships based on reliable precision medical technology”

Gradient Bioconvergence (CEO Jin-Geun Lee) announced that it will participate in the '2025 BIO International Convention (BIO USA)' held in Boston, USA from the 16th to the 19th (local time) for the third consecutive year.

Gradient Bioconvergence plans to operate a standalone booth at this conference to introduce patient-derived organoid (PDO) banking, induced pluripotent stem cell (iPSC)-based brain organoids, and AI target discovery platforms, and discuss joint development and related commercialization with global pharmaceutical and bio companies.

Gradient Bioconvergence currently operates the world's largest PDO banking system with over 900 types of PDOs on its own. Each PDO contains patient clinical information and genomic information (NGS), which can be used not only to evaluate the efficacy of new drug candidates but also to discover new targets. In particular, the co-culture model of iPSC-derived microglia and brain organoids can realistically reproduce the neuroinflammatory response seen in most degenerative brain diseases, and is attracting attention as a platform suitable for evaluating the efficacy of treatments for brain diseases such as Alzheimer's and Parkinson's.

In addition, the company's target discovery platform, which uses PDO big data and self-developed AI algorithms, has applied various analysis algorithms and statistical filtering in stages, and discovers highly reliable anticancer targets in previously difficult-to-access genomic areas. The discovered targets have the advantage of being subject to target validation and selection in human-derived environments from the early stages of verification through the PDO-based CRISPR system.

In fact, Gradient Bioconvergence is currently developing a non-small cell lung cancer treatment based on 'GBC-11004', a novel kinase target derived through the platform, and is actively seeking global joint development partnerships based on various new drug candidates derived from targets discovered in-house.

“As the U.S. Food and Drug Administration (FDA) recently began phasing out animal testing requirements for new drug development and shifting to an evaluation centered on ‘Weight of Evidence,’ including human-based models, interest in organoid platforms is rapidly increasing in the global pharmaceutical industry,” said Lee Jin-geun, CEO of Gradient Bioconvergence. “We will actively expand global collaboration based on precision medicine-based models that reflect actual clinical responses.”